# News Release

DuPont Protection Technologies

Contact: Deborah McNeil
804-383-3292
deborah.s.mcneil-1@dupont.com

**DuPont Protection Technologies Announces Availability of DuPont™ Tyvek® Transition Protocol Materials**

***A Significant Step in the Medical Packaging Transition Project***

WILMINGTON, Del., July 30, 2013 – In 2011 DuPont Protection Technologies announced the Medical Packaging Transition Project, a multi-year investment of more than $30 million to transition DuPont™ Tyvek® 1073B and 1059B materials to the latest flash-spun technology and equipment, to ensure the continuity and flexibility of future supply into medical and pharmaceutical packaging applications worldwide. Today DuPont announces the availability of the Tyvek® Transition Protocol Materials to support medical device manufacturers with their risk assessments; quality management and change control systems as well as allowing them to qualify the material for new device packages. While the material is representative of what will be commercially available in the future, it is not intended for use in packaging of existing commercial devices until all applicable regulations in the country of sale have been met.

"We are excited to have reached this major milestone and are on target for full commercialization in early 2015," said Roseann Salasin, global marketing director, DuPont Protection Technologies. "The Medical Packaging Transition Project is a global collaboration engaging more than 50 organizations including regulatory bodies, test houses, sterile packaging manufacturers and medical device manufacturers. DuPont appreciates the efforts of all these entities as we work together to meet the needs of a growing global population for safe and sustainable medical packaging solutions."

Over the next year DuPont and participating companies will be conducting a multitude of tests of Tyvek® Transition Protocol Material made on the company's newer assets, including the U.S. FDA approved Tyvek® Transition Protocol testing. The purpose of this broad-based testing is to minimize the effort and cost of conversion for the healthcare packaging industry. The purpose of making Tyvek® Transition Protocol Material available is to allow medical device manufacturers to perform additional testing as desired or to qualify the material for any new medical device packaging where needed prior to full commercialization.

Medical and pharmaceutical device manufacturers can purchase Tyvek® Transition Protocol Material from their sterile packaging manufacturers. Sterile packaging manufacturers (SPMs) can purchase the material directly from DuPont by referencing the new and unique SKU numbers that have been provided to them

in a separate communication. The Tyvek® Transition Materials will be sold under a "controlled sales" process. DuPont encourages device manufacturers to communicate their needs for this material to their SPM as soon as possible. Interested organizations can go to www.transition.tyvek.com for additional information on the DuPont Medical Packaging Transition Project including regulatory information, testing protocol information, the latest product testing results and to request a meeting with one of our global Tyvek® transition team experts who can help guide you through the process.

DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.

# # #

7/30/13